31 completed. 31 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 31 | Completed 31 |
| Phase 2 | 3 | Completed 3 |
Follow Meningococcal Meningitis: new trials by email Literature Review of Meningococcal Meningitis trials Research Report on Meningococcal Meningitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 7 to 17 Year Olds MCV4, MPSV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 840 | 2024-12-14 | 2026-08-06 |
| A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4), batch 2 of MCV4, batch 3 of MCV4 - Meningococcal Meningitis | Phase 3 | Completed | CanSino Biologics Inc. | 1480 | 2024-03-20 | 2026-08-06 |
| Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5) NmCV-5, Menactra - Meningococcal Meningitis | Phase 3 | Completed | Serum Institute of India Pvt. Ltd. | 1800 | 2019-08-20 | 2021-07-27 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal polysaccharide groups A, C, W-135 and Y Conjugate vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 918 | 2017-02-24 | 2022-04-05 |
| Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1000 | 2017-02-17 | 2022-03-28 |
| Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 3344 | 2016-07-15 | 2022-04-05 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 907 | 2016-07-15 | 2022-04-05 |
| Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 810 | 2016-04-15 | 2022-04-05 |
| Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28 Bexsero® vaccine (1 dose at study month zero), Bexsero® vaccine (2 doses 1 month apart) - Meningoccocal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 851 | 2013-06-01 | 2021-11-30 |
| A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults Recombinant meningococcal B + OMV NZ - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 18 | 2013-05-01 | 2015-03-27 |
| Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, 2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 805 | 2012-11-01 | 2015-01-13 |
| Comparison of Two Meningococcal ACWY Conjugate Vaccines Menveo, MenACWY-TT - Meningococcal Meningitis | Phase 2 / Phase 3 | Completed | Public Health England | 91 | 2012-06-01 | 2020-10-01 |
| Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects Meningococcal polysaccharide diphtheria toxoid conjugate - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 200 | 2012-01-01 | 2013-05-28 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine MenACWY-CRM, Combined inactivated hepatitis A & recombinant hepatitis B, Recombinant hepatitis B vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 252 | 2011-10-01 | 2017-06-08 |
| Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years Serogroup B meningococcal vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 344 | 2011-08-01 | 2015-02-20 |
| A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years rMenB + OMV NZ vaccine, Meningococcal C oligosaccharide conjugated vaccine, Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 1409 | 2011-04-01 | 2016-05-09 |
| A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea Novartis MenACWY-CRM, Saline Placebo - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 450 | 2010-12-01 | 2012-10-16 |
| Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life MenACWY-CRM, Routine Vaccines - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis Vaccines | 751 | 2010-10-01 | 2018-10-09 |
| Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 No Vaccine, rMenB+OMV-NZ - Meningococcal Disease, Meningococcal Meningitis | Phase 2 / Phase 3 | Completed | Novartis Vaccines | 817 | 2010-08-01 | 2018-06-15 |
Showing 20 of 31. Sign in to see all of them.
Meningitis, Meningococcal (31) · Meningococcal Infections (19) · Meningitis (17) · Chickenpox (3) · Haemophilus Infections (3) · Measles (3) · Mumps (3) · Rubella (3) · Encephalitis, Japanese (1) · Hepatitis A (1) · Hepatitis B (1) · Papillomavirus Infections (1) · Rabies (1) · Tetanus (1) · Typhoid Fever (1)
Bacterial Infections (31) · Bacterial Infections and Mycoses (31) · Central Nervous System Bacterial Infections (31) · Central Nervous System Diseases (31) · Central Nervous System Infections (31) · Gram-Negative Bacterial Infections (31) · Infections (31) · Meningitis, Bacterial (31) · Neisseriaceae Infections (31) · Nervous System Diseases (31) · Neuroinflammatory Diseases (31) · Meningitis (14) · Meningococcal Infections (12) · Virus Diseases (6) · DNA Virus Infections (5)
Meningococcal Vaccines (11) · MenACWY-CRM vaccine (4) · measles, mumps, rubella, varicella vaccine (3) · 4CMenB vaccine (1) · CRM197 (non-toxic variant of diphtheria toxin) (1) · Diphtheria Toxoid (1) · Hepatitis A Vaccines (1) · Hepatitis B Vaccines (1) · Heptavalent Pneumococcal Conjugate Vaccine (1) · Japanese Encephalitis Vaccines (1) · NmCV-5 vaccine (1) · Rabies Vaccines (1) · Vi polysaccharide vaccine, typhoid (1) · Yellow Fever Vaccine (1) · tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (1)
Novartis Vaccines (16) · Sanofi Pasteur, a Sanofi Company (9) · CanSino Biologics Inc. (2) · Novartis (2) · Public Health England (1) · Serum Institute of India Pvt. Ltd. (1)
United States (11) · Germany (5) · Spain (5) · Italy (4) · Puerto Rico (4) · Czechia (3) · Hungary (3) · United Kingdom (3) · Canada (2) · Chile (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · China (1)
Elizabeth Miller, MD (1) · Isti Suharjanti, Dr (1) · Zhiqiang Xie (1)
PMID 29253560, PMID 19476428, PMID 19812260, PMID 20164251, PMID 20189491, PMID 20655261, PMID 21339701, PMID 24873986, PMID 25308927, PMID 25483566, PMID 26075813, PMID 26232542, PMID 26479973, PMID 26756390, PMID 28318767, PMID 29038320, PMID 31279564, PMID 31327652, PMID 32209015, PMID 32387012, PMID 32852352, PMID 33020485, PMID 33325757, PMID 37224196, PMID 37256991, PMID 37256992
2005 (1), 2009 (1), 2016 (1), 2018 (1)